Disclosure Of Interests In Other Entities [Text Block]
| Concept |
As at 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
As at 2021-12-31 |
2021-01-01 to 2021-12-31 |
2021-01-01 to 2021-12-31 |
2021-01-01 to 2021-12-31 |
2021-01-01 to 2021-12-31 |
2021-01-01 to 2021-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disclosure of interests in other entities [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of interests in subsidiaries [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of subsidiaries [text block] | — | — |
und ihre 100%igen Tochtergesellschaften Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, und Biofrontera Neuroscience GmbH,
|
— | — | — | — | — | — | — | — | — |
| Disclosure of subsidiaries [abstract] | ||||||||||||
| Disclosure of subsidiaries [line items] | ||||||||||||
| Profit (loss), attributable to non-controlling interests | — | — |
0
EUR
|
— | — | — | — | — | — | — | — |
4,461
EUR
|
| Current assets |
15,056
EUR
|
— | — | — | — | — |
14,377
EUR
|
— | — | — | — | — |
| Non-current assets |
17,669
EUR
|
— | — | — | — | — |
61,750
EUR
|
— | — | — | — | — |
| Current liabilities |
8,387
EUR
|
— | — | — | — | — |
17,467
EUR
|
— | — | — | — | — |
| Non-current liabilities |
4,002
EUR
|
— | — | — | — | — |
1,235
EUR
|
— | — | — | — | — |
| Revenue | — | — |
25,738
EUR
|
— | — | — | — | — | — | — | — |
28,787
EUR
|
| Profit (loss) | — |
0
EUR
|
44,166
EUR
|
44,166
EUR
|
0
EUR
|
0
EUR
|
— | — | — | — | — |
33,286
EUR
|
| Comprehensive income | — |
0
EUR
|
44,166
EUR
|
44,166
EUR
|
0
EUR
|
0
EUR
|
— |
33,286
EUR
|
0
EUR
|
1,866
EUR
|
0
EUR
|
31,420
EUR
|
| Disclosure of interests in associates [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of associates [text block] | — | — |
Die Finanzanlagen beinhalten den Beteiligungsbuchwert der Biofrontera Inc. in Höhe von 8.982 TEUR (Vorjahr: 53.154 TEUR), die nach der At-Equity-Methode in den Konzernabschluss einbezogen und bewertet wird:
|
— | — | — | — | — | — | — | — | — |
| Disclosure of associates [abstract] | ||||||||||||
| Disclosure of associates [line items] | ||||||||||||
| Other comprehensive income | — |
0
EUR
|
0
EUR
|
0
EUR
|
0
EUR
|
0
EUR
|
— |
0
EUR
|
0
EUR
|
1,866
EUR
|
0
EUR
|
1,866
EUR
|
| Investments accounted for using equity method |
8,982
EUR
|
— | — | — | — | — |
53,154
EUR
|
— | — | — | — | — |
| Disclosure of interests in joint arrangements [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of joint ventures [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of joint ventures [abstract] | ||||||||||||
| Disclosure of joint ventures [line items] | ||||||||||||
| Cash and cash equivalents |
6,376
EUR
|
— | — | — | — | — |
6,908
EUR
|
— | — | — | — | — |
| Other current financial liabilities |
26,000
EUR
|
— | — | — | — | — |
14,000
EUR
|
— | — | — | — | — |
| Other non-current financial liabilities |
0
EUR
|
— | — | — | — | — |
384,000
EUR
|
— | — | — | — | — |
| Interest income | — | — |
1,000
EUR
|
— | — | — | — | — | — | — | — |
13,000
EUR
|
| Interest expense | — | — |
163,000
EUR
|
— | — | — | — | — | — | — | — |
3,692
EUR
|
| Tax expense (income) | — | — |
956,000
EUR
|
— | — | — | — | — | — | — | — |
2,397
EUR
|
| Disclosure of investment entities [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of effect of change of investment entity status on financial statements [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Gain (loss) on cessation of consolidation of subsidiaries due to change of investment entity status | — | — | — | — | — | — | — |
4,177
EUR
|
0
EUR
|
0
EUR
|
0
EUR
|
4,177
EUR
|